Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00276-0/fulltext